Research
Metabolic adaptation
Weight-lowering approaches such as bariatric surgery and treatment with semaglutide and tirzepatide can alleviate both cardiovascular diseases (CVD) and nonalcoholic fatty liver disease (NAFLD).
Practitioners should consider weight loss interventions as effective strategies for managing NAFLD and CVD.
StrongSupportsmedium confidence
Consistently, weight-lowering approaches that can pronouncedly decrease body weight and maintain it in the long term, such as bariatric surgery and treatment with semaglutide and tirzepatide, have been promising in alleviating both CVD and NAFLD.
Why this rating
The abstract discusses established treatments with clinical relevance.
Source
Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective
Moein Ala et al. · Obesity Reviews · 2023
reviewCited 11×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →